To evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of rhASM
in adult patients with Acid Sphingomyelinase Deficiency (ASMD) following repeated-dose
Drug: Recombinant human acid sphingomyelinase
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01722526
Ages eligible for Study
18 Years to 65 Years
Genders eligible for Study
Accepts Healthy Volunteers
Patients with documented non-neuronopathic acid sphingomyelinase deficiency
The patient has a diffusing capacity of carbon monoxide (DLco) >20% and ≤80% of the predicted normal value.
The patient has a spleen volume ≥6 multiples of normal(MN). A partial splenectomy will be permitted if performed ≥1 year prior to Screening/Baseline and residual spleen volume is ≥6 MN.
The patient who is receiving lipid lowering therapy should be on a stable dose and regimen of lipid-lowering therapy(ies) for at least 12 weeks prior to Screening/Baseline, with the patient expected to remain on the same dose and regimen throughout the 26-week treatment period.
The patient who is female and of childbearing potential must have a negative serum pregnancy test for β-HCG.
The patient is female and pregnant or lactating.
The patient has a Body Mass Index(BMI)>30.
The patient has received an investigational drug within 30 days prior to study enrollment
The patient has a medical condition or any extenuating circumstance that may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities.
The patient has had a major organ transplant
ALT or AST >250 IU/L or total bilirubin >1.5 mg/dL.
The patient is unwilling or unable to abstain from the use of alcohol for 1 day prior to and 3 days after each rhASM infusion for the duration of the study.
The patient requires medications that may decrease rhASM
The patient is unwilling or unable to avoid the use of medications or herbal supplements that may cause or prolong bleeding, or have potential hepatotoxicity within 10 days prior to and 3 days after liver biopsy
All locations for NCT01722526
United States (1)
Mount Sinai School of Medicine
New York, New York, United States
United Kingdom (1)
St. Mary's Hospital
Manchester, United Kingdom
View full eligibility
Tris trial is registered with FDA with number: NCT01722526. The sponsor of the trial is Genzyme, a Sanofi Company and it is looking for 5 volunteers for the current phase.
Official trial title: An Open-label, Multicenter, Ascending Dose Study of the Tolerability and Safety of Recombinant Human Acid Sphingomyelinase (rhASM) in Patients With Acid Sphingomyelinase Deficiency (ASMD)
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.